Porphyria Clinical Trial
OBJECTIVES:
Assess whether chronic administration of gonadotropin-releasing hormone analogues is safe
and effective for the prevention of cyclic attacks of acute porphyria in women.
PROTOCOL OUTLINE: All patients receive a gonadotropin-releasing hormone (GnRH) analogue.
Treatment begins on days 1 to 3 of a menstrual cycle.
Low-dose estrogen begins at approximately 3 months. All patients must have a daily calcium
intake of at least 1 gram; supplements are allowed.
Patients are followed for at least 1 year.
;
Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00004396 -
Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias
|
Phase 2 | |
| Recruiting |
NCT00004331 -
Studies in Porphyria I: Characterization of Enzyme Defects
|
N/A | |
| Completed |
NCT00004788 -
Study of Nutritional Factors in Porphyria
|
N/A | |
| Completed |
NCT00004789 -
Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria
|
Phase 1/Phase 2 | |
| Completed |
NCT00004397 -
Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria
|
Phase 1 | |
| Completed |
NCT00004398 -
Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria
|
Phase 1 |